鉴定新型、外切酶结合基质金属蛋白酶-13 抑制剂支架。
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.
机构信息
Department of Chemistry, Scripps Florida, Jupiter, FL 33458, United States.
出版信息
Bioorg Med Chem Lett. 2011 Dec 1;21(23):7180-4. doi: 10.1016/j.bmcl.2011.09.077. Epub 2011 Sep 22.
Abstract
Matrix metalloproteinase-13 (MMP-13) has been implicated as the protease responsible for collagen degradation in cartilage during osteoarthritis (OA). Compounds that inhibit the metalloproteinase at the Zn binding site typically lack specificity among MMP family members. Analogs of the low-micromolar lead MMP-13 inhibitor 4, discovered through high-throughput screening, were synthesized to investigate structure-activity relationships in this inhibitor series. Systematic modifications of 4 led to the discovery of MMP-13 inhibitors 20 and 24 which are more selective than 4 against other MMPs. Compound 20 is also approximately fivefold more potent as an MMP-13 inhibitor than the original HTS-derived lead compound 4.
摘要
基质金属蛋白酶-13（MMP-13）已被认为是骨关节炎（OA）中负责软骨胶原降解的蛋白酶。在 Zn 结合部位抑制金属蛋白酶的化合物通常缺乏 MMP 家族成员之间的特异性。通过高通量筛选发现的低微摩尔级先导 MMP-13 抑制剂 4 的类似物被合成，以研究该抑制剂系列中的构效关系。对 4 的系统修饰导致发现了 MMP-13 抑制剂 20 和 24，它们比 4 对其他 MMP 更具选择性。化合物 20 作为 MMP-13 抑制剂的效力也比原始高通量筛选衍生的先导化合物 4 约高出五倍。
相似文献
1
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.鉴定新型、外切酶结合基质金属蛋白酶-13 抑制剂支架。
Bioorg Med Chem Lett. 2011 Dec 1;21(23):7180-4. doi: 10.1016/j.bmcl.2011.09.077. Epub 2011 Sep 22.
2
High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate.利用三螺旋荧光共振能量转移（FRET）底物对潜在的选择性基质金属蛋白酶-13（MMP-13）别构抑制剂进行高通量筛选。
Bioorg Med Chem. 2009 Feb 1;17(3):990-1005. doi: 10.1016/j.bmc.2008.03.004. Epub 2008 Mar 6.
3
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.基质金属蛋白酶13选择性外位点结合抑制剂的表征，其可在体外防止关节软骨降解。
J Med Chem. 2014 Nov 26;57(22):9598-611. doi: 10.1021/jm501284e. Epub 2014 Nov 11.
4
Cheminformatics-based drug design approach for identification of inhibitors targeting the characteristic residues of MMP-13 hemopexin domain.基于 cheminformatics 的药物设计方法，用于鉴定靶向 MMP-13 血红素结合域特征残基的抑制剂。
PLoS One. 2010 Aug 31;5(8):e12494. doi: 10.1371/journal.pone.0012494.
5
N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.基于N-O-异丙基磺酰胺基的异羟肟酸：作为骨关节炎潜在治疗剂的选择性基质金属蛋白酶-13抑制剂的设计、合成及生物学评价
J Med Chem. 2009 Aug 13;52(15):4757-73. doi: 10.1021/jm900261f.
6
Characterization of an exosite binding inhibitor of matrix metalloproteinase 13.基质金属蛋白酶13的别构结合抑制剂的表征
Protein Sci. 2008 Jan;17(1):66-71. doi: 10.1110/ps.073130208. Epub 2007 Nov 27.
7
The development of new carboxylic acid-based MMP inhibitors derived from a cyclohexylglycine scaffold.基于环己基甘氨酸骨架的新型羧酸类基质金属蛋白酶抑制剂的研发。
Bioorg Med Chem Lett. 2001 Aug 6;11(15):1975-9. doi: 10.1016/s0960-894x(01)00371-7.
8
The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.基于邻氨基苯甲酸的基质金属蛋白酶抑制剂的发现。第3部分：碱性胺的引入。
Bioorg Med Chem Lett. 2001 Nov 19;11(22):2975-8. doi: 10.1016/s0960-894x(01)00601-1.
9
Synthesis and identification of conformationally constrained selective MMP inhibitors.构象受限的选择性基质金属蛋白酶抑制剂的合成与鉴定
Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60. doi: 10.1016/s0960-894x(99)00285-1.
10
The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.基于邻氨基苯甲酸的基质金属蛋白酶抑制剂的发现。第2部分：5位和P1(1)基团的构效关系。
Bioorg Med Chem Lett. 2001 Aug 20;11(16):2189-92. doi: 10.1016/s0960-894x(01)00419-x.
引用本文的文献
1
Molecular Dynamics Simulations of Matrix Metalloproteinase 13 and the Analysis of the Specificity Loop and the S1'-Site.基质金属蛋白酶 13 的分子动力学模拟及特异性环和 S1'位分析。
Int J Mol Sci. 2023 Jun 24;24(13):10577. doi: 10.3390/ijms241310577.
2
In Silico and Experimental ADAM17 Kinetic Modeling as Basis for Future Screening System for Modulators.基于 ADAM17 的计算机模拟和实验动力学建模作为未来调节剂筛选系统的基础。
Int J Mol Sci. 2022 Jan 25;23(3):1368. doi: 10.3390/ijms23031368.
3
Matrix Metalloproteinase 13 Inhibitors for Modulation of Osteoclastogenesis: Enhancement of Solubility and Stability.基质金属蛋白酶 13 抑制剂调节破骨细胞生成：提高溶解度和稳定性。
ChemMedChem. 2021 Apr 8;16(7):1133-1142. doi: 10.1002/cmdc.202000911. Epub 2021 Jan 26.
4
The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma.基质金属蛋白酶抑制剂的复兴：超越教条。
Cells. 2019 Aug 27;8(9):984. doi: 10.3390/cells8090984.
5
Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study.基质金属蛋白酶-13 抑制剂的开发——构效/构性关系研究。
Bioorg Med Chem. 2018 Oct 1;26(18):4984-4995. doi: 10.1016/j.bmc.2018.08.020. Epub 2018 Aug 20.
6
Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors.基于结构的强效和选择性基质金属蛋白酶13抑制剂的设计与合成
J Med Chem. 2017 Jul 13;60(13):5816-5825. doi: 10.1021/acs.jmedchem.7b00514. Epub 2017 Jun 27.
7
Molecular Recognition of the Catalytic Zinc(II) Ion in MMP-13: Structure-Based Evolution of an Allosteric Inhibitor to Dual Binding Mode Inhibitors with Improved Lipophilic Ligand Efficiencies.基质金属蛋白酶-13中催化锌（II）离子的分子识别：基于结构的变构抑制剂向具有改善亲脂性配体效率的双结合模式抑制剂的进化。
Int J Mol Sci. 2016 Mar 1;17(3):314. doi: 10.3390/ijms17030314.
8
SAR Studies of Exosite-Binding Substrate-Selective Inhibitors of A Disintegrin And Metalloprotease 17 (ADAM17) and Application as Selective in Vitro Probes.去整合素和金属蛋白酶17（ADAM17）的外位点结合底物选择性抑制剂的构效关系研究及其作为选择性体外探针的应用
J Med Chem. 2015 Aug 13;58(15):5808-24. doi: 10.1021/acs.jmedchem.5b00354. Epub 2015 Aug 4.
9
Potential clinical implications of recent matrix metalloproteinase inhibitor design strategies.近期基质金属蛋白酶抑制剂设计策略的潜在临床意义。
Expert Rev Proteomics. 2015;12(5):445-7. doi: 10.1586/14789450.2015.1069190. Epub 2015 Jul 15.
10
New strategies for targeting matrix metalloproteinases.靶向基质金属蛋白酶的新策略。
Matrix Biol. 2015 May-Jul;44-46:239-46. doi: 10.1016/j.matbio.2015.01.002. Epub 2015 Jan 14.
本文引用的文献
1
Orally active MMP-1 sparing α-tetrahydropyranyl and α-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.具有治疗癌症、关节炎和心血管疾病功效的口服活性 MMP-1 保护的 α-四氢吡喃基和 α-哌啶基砜基质金属蛋白酶 (MMP) 抑制剂。
J Med Chem. 2010 Sep 23;53(18):6653-80. doi: 10.1021/jm100669j.
2
SAR studies of non-zinc-chelating MMP-13 inhibitors: improving selectivity and metabolic stability.基质金属蛋白酶-13（MMP-13）非锌螯合抑制剂的 SAR 研究：提高选择性和代谢稳定性。
Bioorg Med Chem Lett. 2010 Sep 1;20(17):5039-43. doi: 10.1016/j.bmcl.2010.07.036. Epub 2010 Jul 15.
3
Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.发现（吡啶-4-基）-2H-四唑作为一种新型支架，可鉴定用于治疗骨关节炎的高度选择性基质金属蛋白酶-13 抑制剂。
Bioorg Med Chem Lett. 2010 Jan 15;20(2):576-80. doi: 10.1016/j.bmcl.2009.11.081. Epub 2009 Nov 22.
4
Novel selective MMP-13 inhibitors reduce collagen degradation in bovine articular and human osteoarthritis cartilage explants.新型选择性 MMP-13 抑制剂可减少牛关节软骨和人骨关节炎软骨外植体中的胶原降解。
Inflamm Res. 2010 May;59(5):379-89. doi: 10.1007/s00011-009-0112-9. Epub 2009 Nov 10.
5
To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition.结合锌还是不结合锌：对改进金属蛋白酶抑制作用的创新方法的研究。
Biochim Biophys Acta. 2010 Jan;1803(1):72-94. doi: 10.1016/j.bbamcr.2009.08.006. Epub 2009 Aug 25.
6
Improving potency and selectivity of a new class of non-Zn-chelating MMP-13 inhibitors.提高一类新型非锌螯合基质金属蛋白酶-13抑制剂的效力和选择性。
Bioorg Med Chem Lett. 2009 Sep 15;19(18):5321-4. doi: 10.1016/j.bmcl.2009.07.151. Epub 2009 Aug 3.
7
Matrix metalloproteinase proteomics: substrates, targets, and therapy.基质金属蛋白酶蛋白质组学：底物、靶点与治疗
Curr Opin Cell Biol. 2009 Oct;21(5):645-53. doi: 10.1016/j.ceb.2009.06.006. Epub 2009 Jul 16.
8
Identification of specific hemopexin-like domain residues that facilitate matrix metalloproteinase collagenolytic activity.鉴定有助于基质金属蛋白酶胶原溶解活性的特定血红素结合蛋白样结构域残基。
J Biol Chem. 2009 Sep 4;284(36):24017-24. doi: 10.1074/jbc.M109.016873. Epub 2009 Jul 1.
9
A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis: Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models.一类新型强效基质金属蛋白酶13抑制剂用于骨关节炎的潜在治疗：大鼠模型中组织学和临床疗效证据及无肌肉骨骼毒性
Arthritis Rheum. 2009 Jul;60(7):2008-18. doi: 10.1002/art.24629.
10
Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis.三种不同类风湿关节炎动物模型中 MMP-13 高选择性抑制剂的口服给药效果。
Ann Rheum Dis. 2010 May;69(5):898-902. doi: 10.1136/ard.2008.106021. Epub 2009 Jun 3.
Zotero 插件